21:21 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Vertex discontinues development of spinal cord injury compound VX-210

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) discontinued development of acute spinal cord injury candidate VX-210 after a DSMB recommended stopping a Phase IIb trial for futility following an interim analysis. Vertex has rights to VX-210 from BioAxone...
18:34 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

Apellis pauses Phase III trials after single lot of APL-2 causes inflammation

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) voluntarily paused dosing in Phase III trials of intravitreal APL-2 to treat geographic atrophy due to eight reported cases of non-infectious inflammation in patients treated from a single manufacturing lot of...
18:48 , Oct 18, 2018 |  BC Extra  |  Clinical News

Apellis pauses Phase III trials after single lot of APL-2 causes inflammation

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) lost $2.85 (17%) to $13.86 on Thursday after it voluntarily paused dosing in Phase III trials of intravitreal APL-2 to treat geographic atrophy due to eight reported cases of non-infectious inflammation...
19:30 , Jun 15, 2018 |  BC Week In Review  |  Company News

ChemoCentryx, Vifor Fresenius expand CCX140, avocapan deal to include China

ChemoCentryx Inc. (NASDAQ:CCXI) granted Vifor Fresenius Medical Care Renal Pharma Ltd. exclusive rights to commercialize avacopan (CCX168) and CCX140 in China under the second expansion of a 2016 deal. Vifor Fresenius gained exclusive commercialization rights...
19:36 , Apr 20, 2018 |  Completed Offerings  |  Completed Offerings

Apellis raises $140.3M in follow-on

Autoimmune company Apellis Pharmaceuticals Inc. (NASDAQ:APLS) raised $140.3 million late on April 18 through the sale of 5.5 million shares at $25.50 in a follow-on underwritten by Citigroup, J.P. Morgan and Cowen. The price is...
17:58 , Apr 20, 2018 |  Clinical Results  |  Clinical Results

Apellis reports additional Phase Ib data for C3 inhibitor in PNH

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported data from eight evaluable patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received Soliris eculizumab in the open-label, New Zealand Phase Ib PADDOCK trial showing that once-daily 270...
20:27 , Apr 19, 2018 |  BC Extra  |  Financial News

Apellis raises $140.3M in follow-on

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) raised $140.3 million late Wednesday through the sale of 5.5 million shares at $25.50 in a follow-on underwritten by Citigroup, J.P. Morgan and Cowen. The price is a 15% discount to...
20:56 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Amyndas reports Phase I data for C3 inhibitor AMY-101

Amyndas Pharmaceuticals S.A. (Glyfada, Greece) reported data from an open-label, U.S. Phase I trial in healthy male volunteers showing that single and multiple ascending doses of subcutaneous and IV AMY-101 achieved a "very good safety...
21:23 , Feb 26, 2018 |  BC Extra  |  Company News

Achillion rises on positive opinion for C3G therapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said EMA's Committee for Orphan Medicinal Products issued a positive opinion recommending Orphan Drug designation for ACH-4471 to treat C3 glomerulopathy. Achillion gained $0.46 (15%) to $3.41 on Monday. ACH-4471 is...
20:35 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Apellis reports 18-month Phase II data for GA candidate

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported 18-month data from the Phase II FILLY trial to treat geographic atrophy showing that APL-2 for 12 months maintained significant reductions in lesion growth at six months after stopping treatment....